MedTrace Logo

Repeat Dose Study in Male Healthy Volunteer Smokers

NCT00615576 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2017-08-08

No results posted yet for this study

Summary

This is a 4 to 6 week study to look at the safety and PK profile of SB656933 in healthy male smokers

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

SB-656933

SB-656933 will be available as white film coated, round tablet and will be available in strengths of 50 milligrams, administered orally once daily.

DRUG

Placebo

A placebo tablet to visually match the SB-656933 tablet will also be supplied, administered orally once daily.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-26
Primary Completion
2008-07-24
Completion
2008-07-24

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00615576 on ClinicalTrials.gov